Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study

Claire Harrison, DM, FRCP, FRCPath, Joanna Baxter, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Thomas McKerrell, MD PhD, Aimee Jackson, BSc, MSc, Rachel S Fletcher, PhD, Adam J. Mead, MD PhD, Steve Knapper, BMBCh, MRCP, FRCPath, DM, Joanne Ewing, MD PhD, Nauman M Butt, MD, Manish Jain, MBBS, MRCP, FRCpath, Sebastian Francis, MBChB, FRCPath, MD, Fiona J Clark, FRCP, FRCPath, Jason Coppell, MBBS, Mary Frances McMullin, MDFRCP, FRCPath, Frances Wadelin, MB ChB, PhD FRCPath, Srinivasan Narayanan, FRCP, FRCPath, Dragana Milojkovic, Mark W. Drummond, PhD FRCPath, Mallika Sekhar, MBBS, MD, Maike Paramor, James Roberts, BSc, Rachel Glover, BSc, Erica Harris, MSc, Luigi Grassi, PhD, Alba Rodriguez-Meira, PhD, Jason Carroll, PhD FMedSci, José-Ezequiel Martín, PhD, Giuditta Corbizi Fattori, PhD, Zijian Fang, BSc, Anna L Godfrey, BMBCh, PhD, Simón Méndez-Ferrer, PhD

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-134764

Published: 2020

Journal Articles

The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 10 9 /L to < 100 × 10 9 /L) at Baseline

Paola Guglielmelli, MD, Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Ming-hui Duan, MD, Haitao Meng, MD PhD, Ling Pan, MD PhD, Guangsheng He, MD PhD, Srdan Verstovsek, MD PhD, Françoise Boyer-Perrard, MD, Fiorenza Barraco, MD, Dietger Niederwieser, MD PhD, Anna Marina Liberati, MD, Claire Harrison, DM, FRCP, FRCPath, Pantelia Roussou, MSc, Monika Wroclawska, MD, Kevin Majidi, Peter AW te Boekhorst, MD PhD, Heinz Gisslinger, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137742

Published: 2020

Journal Articles

Inhibition of Immune Cell Subsets Is Differentially Affected By Dasatinib Dosage in Patients with Chronic Phase CML

Patrick Harrington, MRCP, FRCPath, Richard Dillon, MA, PhD MRCP, FRCPath, Deepti H. Radia, MRCPI, FRCPath, Donal P. McLornan, MRCP, PhD FRCPath, Philippe Rousselot, MDPhD, Katayoun Rezvani, MD PhD, Shahram Kordasti, MD PhD, Claire Harrison, DM, FRCP, FRCPath, Hugues de Lavallade, MD PhD

Blood (2020) 136 (Supplement 1): 51–53.

https://doi.org/10.1182/blood-2020-139501

Published: 2020

Journal Articles

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor

John Mascarenhas, MD, Claire Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD PhD, Ruben Mesa, MD, Rami S. Komrokji, MD, Steffen Koschmieder, MD, Alessandro M. Vannucchi, MD, Tymara Berry, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Libo Sun, PhD, Fei Huang, PhD, Ying Wan, PhD, Faye Feller, MD, Aleksandra Rizo, MD PhD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-138915

Published: 2020

Journal Articles

Direct Oral Anticoagulants for Myeloproliferative Neoplasms (MPN-DOACs): Results from an International Study on 442 Patients

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-139229

Published: 2020

Journal Articles

Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

Andrew Charles Perkins, MBBS,PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Thomas Lehmann, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Andreas Reiter, MD, Vikas Gupta, MD FRCP, FRCPath, Claire Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Marielle Wondergem, MD, Robert Pack, PhD, Monika Wroclawska, MD, Celine Wilke, MD, Angela Zhang, PhD, Florian H. Heidel, MD

Blood (2020) 136 (Supplement 1): 52–53.

https://doi.org/10.1182/blood-2020-140408

Published: 2020

Journal Articles

Molecular Characterisation of Participants in the Phazar Trial Reveals Prognostic Impact of Mutations in Advanced-Phase-MPN

Charlotte K Brierley, MRCP, MD, Alba Rodriguez-Meira, PhD, Matthew Bashton, PhD, Angela Hamblin, MD PhD, Rachel S Fletcher, PhD, Sonia Fox, Charlotte Gaskell, BSc, MSc, Aimee Jackson, BSc, MSc, Jennifer O'Sullivan, MD, Lauren C Murphy, Nikolaos Sousos, MDMSc, Amir Enshaei, PhD, Claire Harrison, DM, FRCP, FRCPath, Mark W. Drummond, PhD FRCPath, Steve Knapper, BMBCh, MRCP, FRCPath, DM, Bethan Psaila, MD PhD, Adam J. Mead, MD PhD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-139520

Published: 2020

Journal Articles

Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-137265

Published: 2020

Journal Articles

The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-138752

Published: 2020

Journal Articles

Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial

Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Tamas Masszi, MD, Elena Mishchenko, MD, Mark W. Drummond, PhD FRCPath, Eric Jourdan, MD, Alessandro M. Vannucchi, MD, Mindaugas Jurgutis, Vincent Ribrag, MD, Alessandro Rambaldi, MD PhD, Liang Piu Koh, MBBS, MRCP, Shelonitda Rose, MD, Jun Zhang, PhD, Claire Harrison, DM, FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 10–12.

https://doi.org/10.1182/blood-2020-137279

Published: 2020

Journal Articles

The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis

Naveen Pemmaraju, MD, Jacqueline S. Garcia, MD, Jalaja Potluri, MD, Leanne Holes, BS, MBA,, Jason Harb, PhD, Paul Jung, PhD, Jessica E. Hutti, PhD, Josef T. Prchal, MD, Srdan Verstovsek, MD PhD, Claire Harrison, DM, FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-136938

Published: 2020

Journal Articles

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

Srdan Verstovsek, MD PhD, Miklos Egyed, MD PhD, Ewa Lech-Marańda, MD PhD, Tomasz Sacha, MDPhD, Viviane Dubruille, MD, Stephen T. Oh, MD, Doroteya Todorieva-Todorova, MD, Francesco Passamonti, MD, Blanca Xicoy, MD, Björn Andréasson, MD PhD, Daniel El Fassi, MD, Claire Harrison, DM, FRCP, FRCPath, Donal P. McLornan, MRCP, PhD FRCPath, Mary Frances Frances McMullin, MDFRCPath,FRCP, Christof Scheid, MD, MArianne Tang Severinsen, MD PhD, Mark M Kowalski, MD PhD, Gregg Smith, PhD, Ruben Mesa, MD

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-135872

Published: 2020

Journal Articles

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-138953

Published: 2020

Journal Articles

Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]

Mark W. Drummond, PhD FRCPath, Charlotte Gaskell, BSc, MSc, Claire Harrison, DM, FRCP, FRCPath, Adam J. Mead, MD PhD, Christina Yap, PhD CStat, Aimee E Jackson, BSc, MSc, Jennifer Byrne, FRCP, FRCPath, PhD, Fiona J Clark, FRCP, FRCPath, Srinivasan Narayanan, FRCP, FRCPath, David Bowen, MD, Tim C.P Somervaille, PhD FRCP, FRCPath, Emma Gudgin, MBBS, MRCP, FRCPath, PhD, Dragana Milojkovic, Rachel S Fletcher, PhD, Charlotte K Brierley, MRCP, MD, Steve Knapper, BMBCh, MRCP, FRCPath, DM

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-138437

Published: 2020

Journal Articles

MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients

John Mascarenhas, MD, Claire Harrison, DM, FRCP, FRCPath, Katarina Luptakova, MD, Jessica Christo, MA, Jing Wang, PhD, Jennifer A Mertz, PhD, Gozde Colak, PhD, James Shao, MS, Suresh Bobba, MD, Patrick Trojer, PhD, Adrian Senderowicz, MD, Jeffrey S Humphrey, MD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 43.

https://doi.org/10.1182/blood-2020-140901

Published: 2020

Journal Articles

Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval

Srdan Verstovsek, MD PhD, Shreekant Parasuraman, BPharm, PhD, Jingbo Yu, MD PhD, Anne Shah, Shambhavi Kumar, MS, Ann Xi, PharmD, Claire Harrison, DM, FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-140820

Published: 2020

Journal Articles

Immunocluster: A Computational Tool to Explore the Immune Profile and Cellular Heterogeneity of Hematological Diseases Using Liquid and Imaging Mass, and Flow Cytometry Data

Jessica A. Timms, James W Opzoomer, Kevin Blighe, PhD, Benedetta Apollonio, PhD, Thanos Mourikis, Nicolas Chapuis, PharmD, PhD, Richard Bekoe, Alan G. Ramsay, BSc,MSc,PhD, Donal P. McLornan, MRCP, PhD FRCPath, Claire Harrison, DM, FRCP, FRCPath, Paul R. Barber, Peter Parker, Michaela Fontenay, MD PhD, James N. Arnold, Shahram Kordasti, MD PhD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-140258

Published: 2020

NARROW

Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study

The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 10 9 /L to < 100 × 10 9 /L) at Baseline

Inhibition of Immune Cell Subsets Is Differentially Affected By Dasatinib Dosage in Patients with Chronic Phase CML

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor

Direct Oral Anticoagulants for Myeloproliferative Neoplasms (MPN-DOACs): Results from an International Study on 442 Patients

Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

Molecular Characterisation of Participants in the Phazar Trial Reveals Prognostic Impact of Mutations in Advanced-Phase-MPN

Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study

The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells

Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial

The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients

Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]

MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients

Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval

Immunocluster: A Computational Tool to Explore the Immune Profile and Cellular Heterogeneity of Hematological Diseases Using Liquid and Imaging Mass, and Flow Cytometry Data

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only